within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AA02_Imipramine;

model Imipramine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 1.8999999999999998e-05,
    adminDuration = 600,
    adminMass = 75 / 1000000,
    adminCount = 1,
    Vd = 0.017,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.02,
    Tlag = 600,
    Vdp = 0.053,
    k12 = 4.6666666666666665e-05,
    k21 = 4.6666666666666665e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Imipramine</td></tr><tr><td>ATC code:</td><td>N06AA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>75</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>17</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.14</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Imipramine is a tricyclic antidepressant (TCA) primarily used for the treatment of major depressive disorder and, less commonly, for panic disorder and nocturnal enuresis in children. It acts by inhibiting the reuptake of norepinephrine and serotonin. Imipramine is an approved medication, but its use has declined in favor of selective serotonin reuptake inhibitors due to its side-effect profile.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Abernethy, DR, et al., &amp; Shader, RI (1984). Imipramine disposition in users of oral contraceptive steroids. <i>Clinical pharmacology and therapeutics</i> 35(6) 792–797. DOI:<a href=\"https://doi.org/10.1038/clpt.1984.114\">10.1038/clpt.1984.114</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6734030/\">https://pubmed.ncbi.nlm.nih.gov/6734030</a></p></li><li><p>Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. <i>Clinical pharmacokinetics</i> 42(14) 1243–1285. DOI:<a href=\"https://doi.org/10.2165/00003088-200342140-00004\">10.2165/00003088-200342140-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14606931/\">https://pubmed.ncbi.nlm.nih.gov/14606931</a></p></li><li><p>Sjöqvist, F, &amp; Bertilsson, L (1984). Clinical pharmacology of antidepressant drugs: pharmacogenetics. <i>Advances in biochemical psychopharmacology</i> 39 359–372. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6380229/\">https://pubmed.ncbi.nlm.nih.gov/6380229</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Imipramine;
